Bemarituzumab (Genetical Recombination)



Bemarituzumab is a recombinant anti-fibroblast growth factor receptor 2IIIb (FGFR2IIIb) monoclonal antibody whose complementarity-determining regions are derived from mouse antibody and other regions are derived from human IgG1. Bemarituzumab is produced in glycoprotein 6-α-L-fucosyltransferase-deficient CHO cells. Bemarituzumab is a glycoprotein (molecular weight: ca. 146,000) composed of 2 H-chains (γ1-chains) consisting of 444 amino acid residues each and 2 L-chains (κ-chains) consisting of 214 amino acid residues each.

[1952272-74-0]